OBJECTIVE: To evaluate long-term patient survival and causes of death after open (OR) or endovascular (ER) mesenteric revascularization for atherosclerotic chronic mesenteric ischemia using propensity score-matched comparison and clinical risk stratification. METHODS: The clinical data of 343 patients treated with mesenteric revascularization for chronic mesenteric ischemia between 1991 and 2010 were retrospectively reviewed. Clinical, anatomical, and procedure-related variables were analyzed using a multivariate model to identify independent predictors of any-cause early and late (>30 days) mortality. Cause of death was retrieved from review of the National Death Index. Patient survival was analyzed using Society for Vascular Surgery (SVS) comorbidity scores and propensity score-matched comparison based on independent predictors of any-cause mortality. RESULTS: There were 187 patients treated by OR and 156 patients treated by ER. Early procedure-related mortality was 2.6% (9/343), including five OR (2.7%) and four ER (2.6%) patients. Median follow-up was 96 ± 54 months (range, 1-168 months). There were 144 late deaths, most commonly from cardiac causes in 35% (51/144), followed by cancer in 15% (21/144), pulmonary complications in 13% (19/144), and mesenteric ischemia in 11% (16/144). A further 21 patients died from various identifiable causes, and 14 patients (10%) died of unknown causes. Overall, 25 patients (7.3%) died of mesenteric-related causes, including nine early and 16 late deaths (OR, 10/187; 8.0%, and ER, 6/156; 6.4%). Multivariate analysis identified age >80, diabetes, chronic kidney disease (CKD) stage IV or V, and home oxygen therapy as independent predictors (P < .05) of any cause of death. Diabetes and CKD stage IV or V were independently associated with mesenteric-related death (P < .05). Late patient survival at 5 years in the OR and ER groups was 75% ± 4% and 60% ± 9% for low SVS risk (<9), 52% ± 8% and 43% ± 9% for intermediate SVS risk (9-16), and 67% ± 15% and 30% ± 8% for high SVS risk (>16). Using propensity matched scores, 5-year survival was nearly identical for patients treated by OR (60%) or ER (57%; P = .7). CONCLUSIONS: Long-term patient survival after mesenteric revascularization was not influenced by type of arterial reconstruction. Age >80 years, diabetes, CKD stage IV or V, and home oxygen were independent predictors of any-cause mortality. Diabetes and CKD stage IV or V were independently associated with mesenteric-related death.
OBJECTIVE: To evaluate long-term patient survival and causes of death after open (OR) or endovascular (ER) mesenteric revascularization for atherosclerotic chronic mesenteric ischemia using propensity score-matched comparison and clinical risk stratification. METHODS: The clinical data of 343 patients treated with mesenteric revascularization for chronic mesenteric ischemia between 1991 and 2010 were retrospectively reviewed. Clinical, anatomical, and procedure-related variables were analyzed using a multivariate model to identify independent predictors of any-cause early and late (>30 days) mortality. Cause of death was retrieved from review of the National Death Index. Patient survival was analyzed using Society for Vascular Surgery (SVS) comorbidity scores and propensity score-matched comparison based on independent predictors of any-cause mortality. RESULTS: There were 187 patients treated by OR and 156 patients treated by ER. Early procedure-related mortality was 2.6% (9/343), including five OR (2.7%) and four ER (2.6%) patients. Median follow-up was 96 ± 54 months (range, 1-168 months). There were 144 late deaths, most commonly from cardiac causes in 35% (51/144), followed by cancer in 15% (21/144), pulmonary complications in 13% (19/144), and mesenteric ischemia in 11% (16/144). A further 21 patients died from various identifiable causes, and 14 patients (10%) died of unknown causes. Overall, 25 patients (7.3%) died of mesenteric-related causes, including nine early and 16 late deaths (OR, 10/187; 8.0%, and ER, 6/156; 6.4%). Multivariate analysis identified age >80, diabetes, chronic kidney disease (CKD) stage IV or V, and home oxygen therapy as independent predictors (P < .05) of any cause of death. Diabetes and CKD stage IV or V were independently associated with mesenteric-related death (P < .05). Late patient survival at 5 years in the OR and ER groups was 75% ± 4% and 60% ± 9% for low SVS risk (<9), 52% ± 8% and 43% ± 9% for intermediate SVS risk (9-16), and 67% ± 15% and 30% ± 8% for high SVS risk (>16). Using propensity matched scores, 5-year survival was nearly identical for patients treated by OR (60%) or ER (57%; P = .7). CONCLUSIONS: Long-term patient survival after mesenteric revascularization was not influenced by type of arterial reconstruction. Age >80 years, diabetes, CKD stage IV or V, and home oxygen were independent predictors of any-cause mortality. Diabetes and CKD stage IV or V were independently associated with mesenteric-related death.
Authors: André S van Petersen; Jeroen J Kolkman; Roland J Beuk; Ad B Huisman; Cees J A Doelman; Robert H Geelkerken Journal: J Vasc Surg Date: 2010-03-20 Impact factor: 4.268
Authors: Derek P Nathan; Clayton J Brinster; Edward Y Woo; Jeffrey P Carpenter; Ronald M Fairman; Benjamin M Jackson Journal: J Vasc Surg Date: 2010-11-20 Impact factor: 4.268
Authors: K Kasirajan; P J O'Hara; B H Gray; N R Hertzer; D G Clair; R K Greenberg; L P Krajewski; E G Beven; K Ouriel Journal: J Vasc Surg Date: 2001-01 Impact factor: 4.268
Authors: A H M van Straten; M A Soliman Hamad; B M J A Koene; E J Martens; M E S H Tan; E Berreklouw; A A J van Zundert Journal: Neth Heart J Date: 2011-11 Impact factor: 2.380
Authors: Gustavo S Oderich; Thomas C Bower; Timothy M Sullivan; Haraldur Bjarnason; Stephen Cha; Peter Gloviczki Journal: J Vasc Surg Date: 2009-06 Impact factor: 4.268
Authors: Jeffrey D Pearce; Matthew S Edwards; Jeanette M Stafford; Joel K Deonanan; Ross P Davis; Matthew A Corriere; Teresa A Crutchley; Kimberley J Hansen Journal: Ann Vasc Surg Date: 2007-10-17 Impact factor: 1.466
Authors: Marc L Schermerhorn; Kristina A Giles; Allen D Hamdan; Mark C Wyers; Frank B Pomposelli Journal: J Vasc Surg Date: 2009-04-16 Impact factor: 4.268
Authors: Marvin D Atkins; Christopher J Kwolek; Glenn M LaMuraglia; David C Brewster; Thomas K Chung; Richard P Cambria Journal: J Vasc Surg Date: 2007-04-30 Impact factor: 4.268
Authors: Matthew Huber; Tezcan Ozrazgat-Baslanti; Paul Thottakkara; Philip A Efron; Robert Feezor; Charles Hobson; Azra Bihorac Journal: Ann Vasc Surg Date: 2015-07-14 Impact factor: 1.466
Authors: Miklosh Bala; Fausto Catena; Jeffry Kashuk; Belinda De Simone; Carlos Augusto Gomes; Dieter Weber; Massimo Sartelli; Federico Coccolini; Yoram Kluger; Fikri M Abu-Zidan; Edoardo Picetti; Luca Ansaloni; Goran Augustin; Walter L Biffl; Marco Ceresoli; Osvaldo Chiara; Massimo Chiarugi; Raul Coimbra; Yunfeng Cui; Dimitris Damaskos; Salomone Di Saverio; Joseph M Galante; Vladimir Khokha; Andrew W Kirkpatrick; Kenji Inaba; Ari Leppäniemi; Andrey Litvin; Andrew B Peitzman; Vishal G Shelat; Michael Sugrue; Matti Tolonen; Sandro Rizoli; Ibrahima Sall; Solomon G Beka; Isidoro Di Carlo; Richard Ten Broek; Chirika Mircea; Giovanni Tebala; Michele Pisano; Harry van Goor; Ronald V Maier; Hans Jeekel; Ian Civil; Andreas Hecker; Edward Tan; Kjetil Soreide; Matthew J Lee; Imtiaz Wani; Luigi Bonavina; Mark A Malangoni; Kaoru Koike; George C Velmahos; Gustavo P Fraga; Andreas Fette; Nicola de'Angelis; Zsolt J Balogh; Thomas M Scalea; Gabriele Sganga; Michael D Kelly; Jim Khan; Philip F Stahel; Ernest E Moore Journal: World J Emerg Surg Date: 2022-10-19 Impact factor: 8.165